Immutep Selects Charles River Laboratories for IMP761's GLP Toxicology Study
SYDNEY, AUSTRALIA, May 29, 2023 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces it has entered into an agreement with Charles River under which Charles River will conduct a GLP toxicology study for IMP761, Immutep's proprietary preclinical candidate for autoimmune diseases. IMP761 is a first-in-class LAG-3 agonist antibody that aims to address the underlying cause of many autoimmune diseases, namely the overactivation of self-antigen-specific memory T cells expressing LAG-3.
Preclinical toxicology studies are an essential part of drug development as they help to evaluate the potential safety and toxicity of a drug candidate before it is tested in humans. With its well-established expertise assisting companies in early-stage drug development, Charles River is the partner of choice to help progress our IMP761 program through this key stage of IND-enabling studies.
“Immutep is continuing its pioneering work in the LAG-3 immunotherapy landscape, as we advance IMP761,the world’s first LAG-3 agonist antibody, towards the clinic in the first half of next year. With its novel ability to enhance the signalling of the LAG-3 inhibitory receptor and down-regulate auto-reactive memory T cells at the centre of many autoimmune diseases, we believe IMP761 has the potential to change how immune disorders are treated. We are pleased to be working with an established global company like Charles River for this next important step of our pre-clinical development,” stated Immutep’s Chief Scientific Officer, Frédéric Triebel, M.D., Ph.D.
IMP761’s agonistic activation of LAG-3 is relevant for many diseases, including the Th1-driven autoimmune disease setting. In a pre-clinical oligoarticular juvenile idiopathic arthritis model IMP761 decreased secretion of nearly all measured cytokines, and several key cytokines (IL-10, IL-12, IL-1ß, IL-4, and IL-6) reached the level of statistical-significance (p?<?0.01). These results were published in Pediatric Research in May 2021.
The GLP (Good Laboratory Practice) toxicology results and other preclinical studies will be an essential part of the Company’s clinical trial application for IMP761.
Humanizing Security and Cyber Risks
Special Presentation TBA
BSteeping Success: Bringing Brands into the Metaverse - A Tealet Journey